Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05555290 · ClinicalTrials.gov registry record · Phase 3
PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 190
- Enrollment target
NCT05555290 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 190 participants.
The verdict
NCT05555290, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 190 participants
- Enrollment target
Study Summary
A study evaluating efficacy and safety of repeated doses of PT027 compared to PT007 in patients with asthma and acute airway obstruction induced by repeated mannitol challenges
Interventions
- COMBINATION_PRODUCT PT027
- COMBINATION_PRODUCT PT007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2022-09-28 |
| Est. Completion | 2024-11-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05555290
The ClinicalTrials.gov registry entry for NCT05555290 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PT027 is the first listed.
NCT05555290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05555290 about?
NCT05555290 is a clinical study titled "PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction". A study evaluating efficacy and safety of repeated doses of PT027 compared to PT007 in patients with asthma and acute airway obstruction induced by repeated mannitol challenges
What is the current status of trial NCT05555290?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2022-09-28. Estimated completion is 2024-11-18.
What interventions are being tested in trial NCT05555290?
The interventions under investigation include: PT027 (COMBINATION_PRODUCT), PT007 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05555290?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.